EULAR recommendations for calcium pyrophosphate deposition. Part II: Management

Annals of the Rheumatic Diseases

Volumn 70, Issue 4, 2011, Pages 571-575

  Zhang, Weiya ^a   Doherty, M ^a   Pascual, E ^b   Barskova, V ^c   Guerne, P A ^d   Jansen, T L ^e   Leeb, B F ^f   Perez Ruiz, F ^g   Pimentao, J ^h   Punzi, L ⁱ   Richette, P ^j   Sivera, F ^b   Uhlig, T ^k   Watt, I ^l   Bardin, T ^j  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Lower Austrian Center for Rheumatology   (Austria)

^g HOSPITAL DE CRUCES   (Spain)

^h HOSPITAL EGAS MONIZ   (Portugal)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k DIAKONHJEMMET HOSPITAL   (Norway)

^l LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; DICLOFENAC; HYDROXYCHLOROQUINE; MAGNESIUM SULFATE; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; STEROID; TRIAMCINOLONE ACETONIDE; YTTRIUM 90;

ARTHRITIS; ARTICLE; CALCIUM PYROPHOSPHATE DEPOSITION; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GOUT; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; JOINT ASPIRATION; KIDNEY DISEASE; KNEE OSTEOARTHRITIS; LOADING DRUG DOSE; LOW DRUG DOSE; MEDICAL SOCIETY; NONHUMAN; OSTEOARTHRITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REST; RHEUMATIC DISEASE; SIDE EFFECT; SYNOVECTOMY; SYSTEMATIC REVIEW; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHONDROCALCINOSIS; COLCHICINE; EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; OSTEOARTHRITIS;

EID: 79952359415     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.139360     Document Type: Article

References (51)

1. Zhang W, Doherty M, Bardin T, et al. EULAR recommendations for calcium pyrophosphate crystal associated arthritis. Part I: Terminology and diagnosis. Ann Rheum Dis 2010.
2. Zhang W, Doherty M, Bardin T, et al. EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24. (Pubitemid 44620440)
3. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 2008;16:137-62. (Pubitemid 351222155)
4. Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6. (Pubitemid 39120376)
5. Shekelle P G, Woolf SH, Eccles M, et al. Clinical guidelines: developing guidelines. BMJ 1999;318:593-6.
6. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates 1988.
7. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
8. Kleinbaum DG, Kuppler LL, Morgenstern H. Epidemiologic Research-Principles and Quantitative Methods. Chichester, UK: John Willey & Sons, Inc, 1982.
9. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-81. (Pubitemid 40559291)
10. Roddy E, Zhang W, Doherty M, et al. Evidence-based clinical guidelines: a new system to better determine true strength of recommendation. J Eval Clin Pract 2006;12:347-52. (Pubitemid 43806715)
11. Doherty M, Dieppe PA. Effect of intra-articular yttrium-90 on chronic pyrophosphate arthropathy of the knee. Lancet 1981;2:1243-6. (Pubitemid 12227403)
12. Rothschild B, Yakubov LE. Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD. Compr Ther 1997;23:327-31. (Pubitemid 27255736)
13. Das SK, Mishra K, Ramakrishnan S, et al. A randomized controlled trial to evaluate the slow-acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee. Osteoarthr Cartil 2002;10:247-52. (Pubitemid 34467627)
14. Maldonado MA, Salzman A, Varga J. Intravenous colchicine use in crystal-induced arthropathies: a retrospective analysis of hospitalized patients. Clin Exp Rheumatol 1997;15:487-92. (Pubitemid 27408003)
15. Spilberg I, Berney S. Colchicine and pseudogout. Arthritis Rheum 1979;22:427-8.
16. Tabatabai MR, Cummings NA. Intravenous colchicine in the treatment of acute pseudogout. Arthritis Rheum 1980;23:370-4. (Pubitemid 10134352)
17. Ritter J, Kerr LD, Valeriano-Marcet J, et al. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994;21:696-9. (Pubitemid 24126767)
18. Werlen D, Gabay C, Vischer TL. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. Rev Rhum Engl Ed 1996;63:248-54. (Pubitemid 26160286)
19. Roane DW, Harris MD, Carpenter MT, et al. Prospective use of intramuscular triamcinolone acetonide in pseudogout. J Rheumatol 1997;24:1168-70. (Pubitemid 27250127)
20. Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol 1986;13:804-5. (Pubitemid 16015652)
21. Chollet-Janin A, Finckh A, Dudler J, et al. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum 2007;56:688-92.
22. Trostle D, Schumacher HR. Probenecid therapy of refractory CPPD deposition disease. Arthritis Rheum 1999;42:539.
23. Doherty M, Dieppe PA. Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy. Ann Rheum Dis 1983;42:106-7.
24. Felson DT, Anderson JJ, Naimark A, et al. The prevalence of chondrocalcinosis in the elderly and its association with knee osteoarthritis: the Framingham Study. J Rheumatol 1989;16:1241-5. (Pubitemid 19260115)
25. Neame RL, Carr AJ, Muir K, et al. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis 2003;62:513-18. (Pubitemid 36606282)
26. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthr Cartil 2007;15:981-1000. (Pubitemid 47393443)
27. Landewe RB, Gunther KP, Lukas C, et al. EULAR/EFORT Recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee. Ann Rheum Dis 2010;69:12-19.
28. Schlesinger N, Detry MA, Holland BK, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002;29:331-4. (Pubitemid 34118783)
29. Schlesinger N. Response to application of ice may help differentiate between gouty arthritis and other inflammatory arthritides. J Clin Rheumatol 2006;12:275-6. (Pubitemid 44915324)
30. Cardone DA, Tallia AF. Joint and soft tissue injection. Am Fam Physician 2002;66:283-8.
31. Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987;17:301-4. (Pubitemid 18014682)
32. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 2010;18:476-99.
33. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55. (Pubitemid 37500619)
34. Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:377-88. (Pubitemid 46579641)
35. National Collaborating Centre for Chronic Conditions. Osteoarthritis: National Clinical Guideline for Care and Management in Adults. London: Royal College of Physicians, 2008.
36. Doherty M, Dieppe P, Watt I. Pyrophosphate arthropathy: a prospective study. Br J Rheumatol 1993;32:189-96. (Pubitemid 23089979)
37. Ledingham J, Regan M, Jones A, et al. Factors affecting radiographic progression of knee osteoarthritis. Ann Rheum Dis 1995;54:53-8.
38. Reichenbach S, Blank S, Rutjes AW, et al. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum 2007;57:1410-18. (Pubitemid 350308838)
39. Torres R, Macdonald L, Croll SD, et al. Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis 2009;68:1602-8.
40. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009;68:1613-17.
41. White JC, Brandt FB, Geelhoed GW. Acute pseudogout following parathyroidectomy. Am Surg 1988;54:506-9.
42. Geelhoed GW, Kelly TR. Pseudogout as a clue and complication in primary hyperparathyroidism. Surgery 1989;106:1036-41, discussion 1041-2.
43. Tavill AS. American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. Diagnosis and management of hemochromatosis. Hepatology 2001;33:1321-8.
44. AACE/AAES Task Force on Primary Hyperparathyroidism. The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocrine Practice 2005;11:49-54.
45. Cheng PT, Pritzker KP. The effect of calcium and magnesium ions on calcium pyrophosphate crystal formation in aqueous solutions. J Rheumatol 1981;8:772-82. (Pubitemid 12216376)
46. Bennett RM, Lehr JR, McCarty DJ. Crystal shedding and acute pseudogout. An hypothesis based on a therapeutic failure. Arthritis Rheum 1976;19:93-7.
47. Runeberg L, Collan Y, Jokinen EJ, et al. Hypomagnesemia due to renal disease of unknown etiology. Am J Med 1975;59:873-81.
48. Ho AH, Johson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000;289:165-70.
49. Cini R, Chindamo D, Catenaccio M, et al. Dissolution of calcium pyrophosphate crystals by polyphosphates: an in vitro and ex vivo study. Ann Rheum Dis 2001;60:962-7. (Pubitemid 32885672)
50. Wierzbicki A, Cheung HS. Molecular modeling of inhibition of crystals of calcium pyrophosphate dihydrate by phosphocitrate. J Mol Struct (Theochem) 1998;454:287-97. (Pubitemid 128411956)
51. Salaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol 2005;23:819-28.